Ruijin Hospital: Breast Neoplasms trials

The registry lists 19 Breast Neoplasms studies with Ruijin Hospital as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 2 4Phase 3 2Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionated Proton Radiotherapy in Breast CancerNot yet recruitingNCT07543107
• Proton vs Photon IMRT Toxicity in Breast CancerNot yet recruitingNCT07537712
• Ultra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast CancerRecruitingNCT07527689Not applicable
• Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary IrradiationRecruitingNCT07498855
• Safety and Efficacy of IMPT or IMRT for Breast CancerRecruitingNCT06826885
• A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver MetastasesRecruitingNCT06567353Not applicable
• Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer PatientsRecruitingNCT06404697Phase 2
• Regional Lymph Node Irradiation for High-risk pN0 Breast CancerRecruitingNCT05976412Not applicable
• Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast CancerRecruitingNCT04517266Not applicable
• Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard TreatmentRecruitingNCT03829553Phase 3
• RapidPlan Models Establishment for Node-Positive Breast Cancer Treated With Hypofractionation Using Edge/TruebeamStatus unknownNCT05486936
• Adjuvant Regional Nodal Radiation Therapy for One Week in Breast CancerActive, not recruitingNCT04509648Not applicable
• A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Status unknownNCT04236310Phase 2
• Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast CancerStatus unknownNCT03907800Phase 2
• 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)TerminatedNCT03367676Phase 2
• Pathological Fracture in Potentially Unstable Spinal Metastases of Breast CancerStatus unknownNCT03365973
• The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.Active, not recruitingNCT02942615Not applicable
• Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast CancerCompletedNCT02549677Phase 4
• Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer PatientsTerminatedNCT02532400Phase 3